Opinion

Video

Concurrent NSCLC Biomarker Testing at Diagnosis

Author(s):

Zofia Piotrowska, MD, MHS,Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, shares his approach to optimizing the use of diagnostic testing from both a tissue perspective and cost perspective, noting he routinely orders tissue and liquid biopsies during the initial patient visit if prior testing has not been conducted.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
FDA Orphan Drug Designation for rehnium (186Re) obisbemeda for leptomeningeal metastases in lung cancer
March 12th 2025

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 11th 2025

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

NSCLC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC

Lung Cancer | Image credit: catalin – stock.adobe.com
March 10th 2025

China’s NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC